查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726349

全球下一代组织生物标记市场：市场规模、份额、趋势分析（按产品类型、技术、应用、最终用途和地区）、细分市场预测（2025 年至 2030 年）

Next Generation Tissue Biomarkers Market Size, Share & Trends Analysis Report By Product (Reagents & Assays, Instruments & Platforms), By Type (Genomic, Proteomic), By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

下一代组织生物标记市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球下一代组织生物标记市场规模预计到 2030 年将达到 59.8 亿美元，预测期内的复合年增长率为 12.74%。

慢性病盛行率上升、生物标记检测技术的进步以及个人化医疗需求的不断增长等关键驱动因素正在推动市场成长。糖尿病、癌症和其他自体免疫疾病等慢性疾病的发生率在全球范围内不断增加。

检测下一代组织生物标誌物的技术进步不断推动市场的成长。次世代定序（NGS）等高通量筛检技术的发展，大大提升了我们分析癌症组织中基因突变和基因表现的能力。此外，液态切片、高通量筛检技术、表观遗传分析和基于微型RNA的生物感测器正在投入实用化，用于下一代组织生物标记检测。总的来说，这些技术进步正在改变组织生物标记发现的格局，从而实现更准确的诊断、个人化的治疗策略和改善患者的治疗效果。人工智慧和机器学习演算法正在被纳入数位病理学，以自动分析组织影像。个人化医疗需求的不断成长也是推动市场成长的一个主要因素。在这种个人化医疗中，下一代组织生物标记越来越多地被用于为个别患者量身定制治疗方案。

在生物标记检测方面，表观基因基因体学研究工具公司AlidaBio于2025年2月正式宣布全面商业化其EpiPlex平台。此突破性平台首次透过短读测序同时检测和量化多种RNA修饰，同时也提供基因表现数据。

2025 年 2 月，提供基因组解决方案的公司 Biofidelity 宣布了有关推出 Enspyre 的详细信息，Enspyre 是一项具有广泛应用潜力的创新目标富集技术。一项突破性的目标富集技术，透过选择性去除背景 DNA，显着提高次世代定序(NGS) 的效率。

2024 年 9 月，RNA 生物标记公司 Genialis 宣布推出 Genialis krasID，这是第一个能够预测不同组织类型和突变类型的患者对 KRAS 抑制剂 (KRASi) 的反应和临床效用的生物标记演算法。 Genialis krasID 可以帮助指南药物开发，从早期临床前阶段（例如化合物/MOA 区分和选择）到临床试验。

2024年10月，另一种新型老化细胞标靶分子被开发出来。 Illumina 公司是一家 DNA定序和基于阵列的技术公司，今天推出了 MiSeq i100 系列定序系统，该系统具有无与伦比的台式速度和易用性，可为实验室中的次世代定序(NGS) 提供支援。

2021年9月，罗氏宣布推出AVENIO肿瘤组织CGP试剂盒。新套件增强了罗氏和 Foundation Medicine 现有的 CGP 产品组合，使实验室能够在内部进行更广泛的肿瘤学研究。该公司表示，该套件的推出将为无法透过集中实验室进行公司测试的实验室提供内部解决方案，从而显着增加全球对基因组分析的访问。

下一代组织生物标记市场：分析概述

  • 按产品划分，试剂和测定法在 2024 年占据了最大的收入份额，为 55.97%。由于该领域广泛适用于生物製药研究，预计将迅速扩张。主要驱动因素是对疾病早期检测和诊断的需求不断增加，这反过来又增加了对准确、可靠和快速诊断的需求，从而促进了市场成长。
  • 根据类型，基因生物标誌物部分在 2024 年占据了市场主导地位。这是由于对创新治疗方法的需求不断增长、对早期疾病检测的竞争加剧以及大量的研发投资。预计代谢组生物标记在预测期内增长最快。代谢组学生物标记是对体内特定代谢变化或物质的测量，可用于识别疾病状态、预测疾病风险和监测治疗反应。
  • 从技术角度来看，次世代定序领域在 2024 年占据了市场主导地位，收益占有率最大。次世代定序(NGS) 是指有助于基因组发现的大规模 DNA定序方法。预计 2024 年至 2030 年间，空间基因组生物学领域将以最快的复合年增长率成长。 CRISPR/Cas9 系统等基因组编辑工具的进步正在促进空间基因组生物学的应用，从而推动市场成长。
  • 根据应用，肿瘤学领域在 2024 年占据市场主导地位，收益占有率最大。精准医疗日益增长的需求正在推动该领域和针对性癌症治疗的发展。预计伴随诊断在预测期内成长最快。伴随诊断市场正在经历快速的产品扩张，针对各种癌症类型、自体免疫疾病和神经系统疾病的新检测方法正在开发中。
  • 根据最终用途，医院和参考实验室部门将主导市场，并在 2024 年占据最大的收益占有率。医院和参考实验室正在迅速采用下一代组织生物标记来提高效率、准确性和可近性。预计预测期内 CRO 将大幅成长。

目录

第一章 分析方法与范围

第二章执行摘要

3. 下一代组织生物标记市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 下一代组织生物标记市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章 下一代组织生物标记市场：按产品分類的预测和趋势

  • 细分仪表板
  • 下一代组织生物标记市场：依产品变异分析
  • 下一代组织生物标记市场规模及产品趋势分析（2018-2030）
  • 试剂和测定法
  • 设备和平台
  • 软体和人工智慧

第五章：下一代组织生物标记市场：按类型进行估计和趋势分析

  • 按类型分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 下一代组织生物标记市场：按类型分類的展望
  • 按类型分類的市场规模预测和趋势分析（2018-2030）
  • 基因生物标誌物
  • 蛋白质体生物标记
  • 蛋白质体生物标记
  • 表观遗传生物标记
  • 转录组生物标誌物
  • 代谢体学学生物标誌物

第六章：下一代组织生物标记市场：按技术分類的估值和趋势

  • 按技术分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 下一代组织生物标记市场：依产品变异分析
  • 下一代组织生物标记市场规模与产品趋势分析（2018-2030）
  • 免疫组织化学
  • 次世代定序（NGS）
  • 基于质谱（MS）的蛋白质体学
  • 太空生物学平台
  • 数位病理学和人工智慧分析
  • 其他的

第七章 下一代组织生物标记市场：按应用的估算和趋势分析

  • 按应用分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 下一代组织生物标记市场：按应用进行差异分析
  • 下一代组织生物标记市场规模与应用趋势分析（2018-2030）
  • 瘤
  • 伴随诊断
  • 药物研发
  • 神经病学
  • 其他的

第八章 下一代组织生物标记市场：最终用途估计与趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 下一代组织生物标记市场：按最终用途的变化分析
  • 下一代组织生物标记市场规模和趋势分析（按最终用途） (2018-2030)
  • 医院/参考实验室
  • 製药和生物技术公司
  • 学术研究所
  • CRO（合约业务组织）

第九章：下一代组织生物标记市场：区域估计和趋势分析

  • 各地区市场占有率分析（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • Roche Diagnostics/Ventana Medical Systems
    • Agilent Technologies/Dako
    • Thermo Fisher Scientific
    • Leica Biosystems（Danaher Corporation）
    • Illumina
    • Qiagen
    • NeoGenomics
    • NanoString Technologies
    • Akoya Biosciences
    • Bio-Techne/ACD
    • Guardant Health
Product Code: GVR-4-68040-555-5

Next Generation Tissue Biomarkers Market Growth & Trends:

The global next generation tissue biomarkers market size is anticipated to reach USD 5.98 billion by 2030 and is projected to grow at a CAGR of 12.74% during the forecast period, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.

For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.

In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.

In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.

Next Generation Tissue Biomarkers Market Report Highlights:

  • Based on product, reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to see rapid expansion due to its broad applicability in biopharmaceutical research. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth.
  • Based on type, the genomic biomarker segment dominated the market in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. Metabolomic biomarkers are expected to grow fastest over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments.
  • Based on technology, the next generation sequencing segment dominated the market with the largest revenue share in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. The spatial genomics biology segment is anticipated to witness growth at the fastest CAGR from 2024 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth.
  • Based on application, the oncology segment dominated the market with the largest revenue share in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Companion diagnostics are expected to grow fastest over the forecast period. The companion diagnostics market is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders.
  • Based on end use, the hospitals & reference labs segment dominated the market with the largest revenue share in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. Contract research organizations are projected to grow significantly during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. Type
    • 1.2.5. End Use
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Application outlook
    • 2.2.4. Type outlook
    • 2.2.5. End Use outlook
    • 2.2.6. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Next Generation Tissue Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise of Precision Medicine and Companion Diagnostics
      • 3.2.1.2. Technological Advancements in Spatial Biology and NGS
      • 3.2.1.3. Expansion of Clinical Utility Across Disease Areas
      • 3.2.1.4. Growth in Digital Pathology and AI-Driven Analysis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Multi-Omic Platforms and Reagents
      • 3.2.2.2. Data Privacy and Infrastructure Barriers in AI Adoption
  • 3.3. Next Generation Tissue Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Next Generation Tissue Biomarkers Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Next Generation Tissue Biomarkers Market: Product Movement Analysis
  • 4.3. Next Generation Tissue Biomarkers Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
  • 4.4. Reagents & Assays
    • 4.4.1. Reagents & Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Instruments & Platforms
    • 4.5.1. Instruments & Platforms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Software & AI
    • 4.6.1. Software & AI Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Next Generation Tissue Biomarkers Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Next Generation Tissue Biomarkers Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Genomic Biomarkers
    • 5.5.1. Genomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Proteomic Biomarkers
    • 5.6.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Proteomic Biomarkers
    • 5.7.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Epigenetic Biomarkers
    • 5.8.1. Epigenetic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Transcriptomic Biomarkers
    • 5.9.1. Transcriptomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Metabolomic Biomarkers
    • 5.10.1. Metabolomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Next Generation Tissue Biomarkers Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Next Generation Tissue Biomarkers Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Immunohistochemistry
    • 6.5.1. Immunohistochemistry Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Next-Generation Sequencing (NGS)
    • 6.6.1. Next-Generation Sequencing (NGS) Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Mass Spectrometry (MS)-based Proteomics
    • 6.7.1. Mass Spectrometry (MS)-based Proteomics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Spatial Biology Platforms
    • 6.8.1. Spatial Biology Platforms Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Digital Pathology & AI Analysis
    • 6.9.1. Digital Pathology & AI Analysis Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Next Generation Tissue Biomarkers Market: Application Estimates & Trend Analysis

  • 7.1. Application Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Next Generation Tissue Biomarkers Market by Application Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Oncology
    • 7.5.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Companion Diagnostics
    • 7.6.1. Companion Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Drug Discovery & Development
    • 7.7.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Neurology
    • 7.8.1. Neurology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Next Generation Tissue Biomarkers Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Market Share, 2024 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Next Generation Tissue Biomarkers Market by End Use Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5. Hospitals & Reference Labs
    • 8.5.1. Hospitals & Reference Labs Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Pharma & Biotech Companies
    • 8.6.1. Pharma & Biotech Companies Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Academic and Research Institutes
    • 8.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Contract Research Organizations (CROs)
    • 8.8.1. Contract Research Organizations (CROs) Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Next Generation Tissue Biomarkers Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.5. North America
    • 9.5.1. North America
    • 9.5.2. U.S.
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/Reimbursement
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.3. Canada
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/Reimbursement
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.4. Mexico
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/Reimbursement
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Europe
    • 9.6.1. Europe
    • 9.6.2. UK
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/Reimbursement
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.3. Germany
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework/Reimbursement
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.4. France
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework/Reimbursement
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.5. Italy
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework/Reimbursement
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.6. Spain
      • 9.6.6.1. Key country dynamics
      • 9.6.6.2. Regulatory framework/Reimbursement
      • 9.6.6.3. Competitive scenario
      • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.7. Norway
      • 9.6.7.1. Key country dynamics
      • 9.6.7.2. Regulatory framework/Reimbursement
      • 9.6.7.3. Competitive scenario
      • 9.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.8. Sweden
      • 9.6.8.1. Key country dynamics
      • 9.6.8.2. Regulatory framework/Reimbursement
      • 9.6.8.3. Competitive scenario
      • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.9. Denmark
      • 9.6.9.1. Key country dynamics
      • 9.6.9.2. Regulatory framework/Reimbursement
      • 9.6.9.3. Competitive scenario
      • 9.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7. Asia Pacific
    • 9.7.1. Asia Pacific
    • 9.7.2. Japan
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/Reimbursement
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.3. China
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/Reimbursement
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.4. India
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/Reimbursement
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.5. Australia
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Regulatory framework/Reimbursement
      • 9.7.5.3. Competitive scenario
      • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.6. South Korea
      • 9.7.6.1. Key country dynamics
      • 9.7.6.2. Regulatory framework/Reimbursement
      • 9.7.6.3. Competitive scenario
      • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.7. Thailand
      • 9.7.7.1. Key country dynamics
      • 9.7.7.2. Regulatory framework/Reimbursement
      • 9.7.7.3. Competitive scenario
      • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8. Latin America
    • 9.8.1. Latin America
    • 9.8.2. Brazil
      • 9.8.2.1. Key country dynamics
      • 9.8.2.2. Regulatory framework/Reimbursement
      • 9.8.2.3. Competitive scenario
      • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.3. Argentina
      • 9.8.3.1. Key country dynamics
      • 9.8.3.2. Regulatory framework/Reimbursement
      • 9.8.3.3. Competitive scenario
      • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9. MEA
    • 9.9.1. MEA
    • 9.9.2. South Africa
      • 9.9.2.1. Key country dynamics
      • 9.9.2.2. Regulatory framework/Reimbursement
      • 9.9.2.3. Competitive scenario
      • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.3. Saudi Arabia
      • 9.9.3.1. Key country dynamics
      • 9.9.3.2. Regulatory framework/Reimbursement
      • 9.9.3.3. Competitive scenario
      • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.4. UAE
      • 9.9.4.1. Key country dynamics
      • 9.9.4.2. Regulatory framework/Reimbursement
      • 9.9.4.3. Competitive scenario
      • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.5. Kuwait
      • 9.9.5.1. Key country dynamics
      • 9.9.5.2. Regulatory framework
      • 9.9.5.3. Competitive scenario
      • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2024
    • 10.3.4. Roche Diagnostics / Ventana Medical Systems
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Services benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Agilent Technologies / Dako
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Services benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Thermo Fisher Scientific
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Services benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Leica Biosystems (Danaher Corporation)
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Services benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Illumina
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Services benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Qiagen
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Services benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. NeoGenomics
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Services benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. NanoString Technologies
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Services benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Akoya Biosciences
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Services benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Bio-Techne / ACD
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Services benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Guardant Health
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Services benchmarking
      • 10.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Next Generation Tissue Biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 North America Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 8 U.S Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 9 U.S Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 10 U.S Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 11 U.S Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 13 Canada Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 16 Canada Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 17 Canada Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 18 Mexico Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 20 Mexico Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 Mexico Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 23 Europe Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 24 Europe Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Europe Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 26 Europe Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 27 Europe Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 28 UK Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 29 UK Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 31 UK Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 32 UK Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 33 Germany Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 34 Germany Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 35 Germany Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Germany Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 38 France Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 39 France Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 40 France Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 41 France Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 42 France Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 43 Italy Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 44 Italy Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Italy Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 46 Italy Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 47 Italy Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 48 Spain Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 49 Spain Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Spain Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 Spain Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 Spain Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 53 Denmark Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 54 Denmark Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Denmark Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 57 Denmark Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 58 Sweden Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 59 Sweden Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 60 Sweden Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 61 Sweden Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 62 Sweden Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 63 Norway Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 64 Norway Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 65 Norway Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 66 Norway Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Norway Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 73 Japan Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 74 Japan Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 75 Japan Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 76 Japan Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 77 Japan Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 78 China Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 79 China Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 80 China Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 China Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 China Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 83 India Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 84 India Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 85 India Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 86 India Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 87 India Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 88 Australia Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 89 Australia Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 90 Australia Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 91 Australia Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 92 Australia Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 93 South Korea Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 94 South Korea Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 95 South Korea Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 96 South Korea Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 97 South Korea Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 98 Thailand Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 99 Thailand Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 100 Thailand Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 101 Thailand Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 102 Thailand Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 103 Latin America Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 104 Latin America Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 105 Latin America Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 106 Latin America Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 107 Latin America Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 108 Brazil Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 109 Brazil Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 110 Brazil Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 111 Brazil Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 112 Brazil Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 113 Argentina Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 114 Argentina Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 115 Argentina Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 116 Argentina Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 117 Argentina Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 118 MEA Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 119 MEA Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 120 MEA Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 121 MEA Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 122 MEA Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 123 South Africa Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 124 South Africa Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 125 South Africa Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 126 South Africa Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 127 South Africa Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 128 Saudi Arabia Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 129 Saudi Arabia Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 130 Saudi Arabia Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 131 Saudi Arabia Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 133 UAE Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 134 UAE Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 135 UAE Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 136 UAE Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 137 UAE Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 138 Kuwait Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 139 Kuwait Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 140 Kuwait Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 141 Kuwait Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 142 Kuwait Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Next Generation Tissue Biomarkers market: market outlook
  • Fig. 14 Next Generation Tissue Biomarker competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Next Generation Tissue Biomarkers market driver impact
  • Fig. 20 Next Generation Tissue Biomarkers market restraint impact
  • Fig. 21 Next Generation Tissue Biomarkers market strategic initiatives analysis
  • Fig. 22 Next Generation Tissue Biomarkers market: Product movement analysis
  • Fig. 23 Next Generation Tissue Biomarkers market: Product outlook and key takeaways
  • Fig. 24 Reagents & Assays market estimates and forecast, 2018 - 2030
  • Fig. 25 Instruments & Platforms market estimates and forecast, 2018 - 2030
  • Fig. 26 Software & AI market estimates and forecast, 2018 - 2030
  • Fig. 27 Next Generation Tissue Biomarkers Market: Type movement analysis
  • Fig. 28 Next Generation Tissue Biomarkers market: Type outlook and key takeaways
  • Fig. 29 Genomic Biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 30 Proteomic Biomarkers market estimates and forecasts,2018 - 2030
  • Fig. 31 Epigenetic Biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 32 Transcriptomic Biomarkers market estimates and forecasts,2018 - 2030
  • Fig. 33 Metabolomic Biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 34 Next Generation Tissue Biomarkers Market: Technology movement analysis
  • Fig. 35 Next Generation Tissue Biomarkers market: Technology outlook and key takeaways
  • Fig. 36 Immunohistochemistry market estimates and forecasts, 2018 - 2030
  • Fig. 37 Next-Generation Sequencing (NGS) market estimates and forecasts,2018 - 2030
  • Fig. 38 Mass Spectrometry (MS)-based Proteomics market estimates and forecasts,2018 - 2030
  • Fig. 39 Spatial Biology Platforms market estimates and forecasts,2018 - 2030
  • Fig. 40 Digital Pathology & AI Analysis market estimates and forecasts,2018 - 2030
  • Fig. 41 Others market estimates and forecasts,2018 - 2030
  • Fig. 42 Next Generation Tissue Biomarkers Market: Application movement analysis
  • Fig. 43 Next Generation Tissue Biomarkers market: Application outlook and key takeaways
  • Fig. 44 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 45 Companion Diagnostics market estimates and forecasts,2018 - 2030
  • Fig. 46 Drug Discovery & Development market estimates and forecasts,2018 - 2030
  • Fig. 47 Neurology market estimates and forecasts,2018 - 2030
  • Fig. 48 Others market estimates and forecasts,2018 - 2030
  • Fig. 49 Next Generation Tissue Biomarkers market: End Use movement analysis
  • Fig. 50 Next Generation Tissue Biomarkers market: End Use outlook and key takeaways
  • Fig. 51 Hospitals & Reference Labs market estimates and forecasts, 2018 - 2030
  • Fig. 52 Pharma & Biotech Companies market estimates and forecasts,2018 - 2030
  • Fig. 53 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
  • Fig. 54 Contract Research Organizations (CROs) market estimates and forecasts, 2018 - 2030
  • Fig. 55 Global Next Generation Tissue Biomarkers market: Regional movement analysis
  • Fig. 56 Global Next Generation Tissue Biomarkers market: Regional outlook and key takeaways
  • Fig. 57 Global Next Generation Tissue Biomarkers market share and leading players
  • Fig. 58 North America market share and leading players
  • Fig. 59 Europe market share and leading players
  • Fig. 60 Asia Pacific market share and leading players
  • Fig. 61 Latin America market share and leading players
  • Fig. 62 Middle East & Africa market share and leading players
  • Fig. 63 North America
  • Fig. 64 Europe
  • Fig. 65 Asia Pacific
  • Fig. 66 Latin America
  • Fig. 67 MEA
  • Fig. 68 North America, by country
  • Fig. 69 North America
  • Fig. 70 North America market estimates and forecasts, 2018 - 2030
  • Fig. 71 U.S.
  • Fig. 72 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 73 Canada
  • Fig. 74 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 75 Mexico
  • Fig. 76 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 77 Europe
  • Fig. 78 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 79 UK
  • Fig. 80 UK market estimates and forecasts, 2018 - 2030
  • Fig. 81 Germany
  • Fig. 82 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 83 France
  • Fig. 84 France market estimates and forecasts, 2018 - 2030
  • Fig. 85 Italy
  • Fig. 86 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 87 Spain
  • Fig. 88 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 89 Denmark
  • Fig. 90 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 91 Sweden
  • Fig. 92 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 93 Norway
  • Fig. 94 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 95 Asia Pacific
  • Fig. 96 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 97 China
  • Fig. 98 China market estimates and forecasts, 2018 - 2030
  • Fig. 99 Japan
  • Fig. 100 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 101 India
  • Fig. 102 India market estimates and forecasts, 2018 - 2030
  • Fig. 103 Thailand
  • Fig. 104 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 105 South Korea
  • Fig. 106 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 107 Australia
  • Fig. 108 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 109 Latin America
  • Fig. 110 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 111 Brazil
  • Fig. 112 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 113 Argentina
  • Fig. 114 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 115 Middle East and Africa
  • Fig. 116 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 117 South Africa
  • Fig. 118 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 119 Saudi Arabia
  • Fig. 120 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 121 UAE
  • Fig. 122 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 123 Kuwait
  • Fig. 124 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 125 Market share of key market players - Next Generation Tissue Biomarkers market